Revenue Generating Partnerships
Turn Therapeutics Commercial partnerships that generate revenue without additional capital investment
Proven Execution and
Capital Discipline
Turn Therapeutics has demonstrated the ability to translate innovation into regulated products:
- Three FDA-cleared medical device formulations
- Strategic global partnerships, including a collaboration with Medline
- Zero-capital-intensive device programs that provide revenue and validate execution
These programs are intentionally structured to protect downside, extend runway, and demonstrate regulatory competence, while maintaining clear focus on therapeutic development.
Our model combines:
- First-in-class targeted mechanisms
- Differentiated localized delivery
- Proven regulatory execution
- Intelligent use of non-dilutive partnerships
This structure positions Turn Therapeutics as a capital-efficient leader in targeted therapeutics, capable of supporting multiple strategic outcomes, including partnership, acquisition, or independent advancement.
Built for Capital Efficiency and Strategic Value
Become our
partner
in the new era of topical treatment
Turn Therapeutics maintains commercial partnerships that generate revenue without additional capital investment.
These collaborations support long-term development efforts and demonstrate proven regulatory and operational capability.
Medline partnership overview
FDA Cleared Product
Antimicrobial Oil Emulsion Dressing
Medline’s Global Reach
Potential Future Products
MIMEDX partnership overview
$70M+ Milestone
Antimicrobial Collagen Powder
MIMEDX’s Focus
Potential Future Products
